
南美洲和中美洲胃肠道药物市场预测至 2027 年 - COVID-19 影响和按药物类别(酸中和剂、止泻药和泻药、抗炎药、止吐药和止吐药、生物制剂等)进行的区域分析;给药途径(口服和肠胃外);应用(炎症性溃疡性结肠炎、克罗恩病、肠易激综合症、胃肠炎、乳糜泻等);和分销渠道(医院药房、零售药房和在线药房)以及国家/地区
No. of Pages: 133 | Report Code: TIPRE00016303 | Category: Life Sciences
No. of Pages: 133 | Report Code: TIPRE00016303 | Category: Life Sciences
胃肠道药物包括促动力药、抗动力药和胃酸相关疾病药物。常用的胃肠道药物作为一组被认为是安全的。胃肠道 (GI) 疾病影响胃、胰腺、直肠和大肠、食道、小肠、胆囊和肝脏。胃肠道疾病的主要症状是消化不良、胃灼热、便秘腹胀等。
南美洲和中美洲胃肠道药物市场预计将从 2019 年的 41.6028 亿美元增至 2027 年的 56.3272 亿美元。预计 2019-2027 年该市场将以 4.0% 的复合年增长率增长。胃肠道(GI)疾病患病率的上升以及生物制剂开发的增加是预计推动南美洲和中美洲胃肠道药物市场增长的主要因素。然而,在预测期内,市场可能会受到药物副作用等风险因素的影响。
从药品类别来看,2019年南美洲和中美洲胃肠道药物市场中酸中和剂细分市场份额最大。从给药途径来看,口服细分市场份额最大。 2019年南美和中美洲胃肠道药物市场。从应用来看,炎症性溃疡性结肠炎细分市场占2019年南美和中美洲胃肠道药物市场的最大份额。从分销渠道来看,零售药房细分市场占2019 年南美洲和中美洲胃肠道药物市场份额最大。
与南美洲和中美洲胃肠道药物市场报告相关的几个主要一手和二手来源是世界卫生组织 (WHO)、美洲心脏基金会 (FIC)、巴西卫生监管机构、国际胃肠道疾病基金会等。
Strategic insights for South & Central America Gastrointestinal Drugs involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2019 | US$ 4,160.28 Million |
Market Size by 2027 | US$ 5,632.72 Million |
Global CAGR (2019 - 2027) | 4.0% |
Historical Data | 2017-2018 |
Forecast period | 2020-2027 |
Segments Covered |
By 药物类别
|
Regions and Countries Covered | 南美洲和中美洲
|
Market leaders and key company profiles |
The regional scope of South & Central America Gastrointestinal Drugs refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The South & Central America Gastrointestinal Drugs Market is valued at US$ 4,160.28 Million in 2019, it is projected to reach US$ 5,632.72 Million by 2027.
As per our report South & Central America Gastrointestinal Drugs Market, the market size is valued at US$ 4,160.28 Million in 2019, projecting it to reach US$ 5,632.72 Million by 2027. This translates to a CAGR of approximately 4.0% during the forecast period.
The South & Central America Gastrointestinal Drugs Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South & Central America Gastrointestinal Drugs Market report:
The South & Central America Gastrointestinal Drugs Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South & Central America Gastrointestinal Drugs Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South & Central America Gastrointestinal Drugs Market value chain can benefit from the information contained in a comprehensive market report.